In reply
We do not agree with Hansen. The CAPRIE subgroup analyses that we presented in our article did demonstrate a statistically significant reduction in ischemic events with clopidogrel vs aspirin, as was also seen in the overall CAPRIE analysis, though of a different magnitude.1-6 Furthermore, bleeding rates and rehospitalization for bleeding were lower, not higher, with clopidogrel than with aspirin.2,6 In fact, the whole point of the article was that high-risk subgroups appear to derive a larger degree of benefit from more potent antiplatelet therapy.